In addition, in the current era of CDK4/6 inhibitors, the activity of fulvestrant on ER-positive breast cancer (both the wild-type ESR1 and the ESR1 mutant) after tumor progression on CDK4/6 inhibitors appears limited. This evidence concerns the gene CDK4 and neoplasm.